PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.562201951143-52Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Rohttp://e-crt.org/upload/pdf/crt-2017-562.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.562, http://www.e-crt.org/upload/pdf/crt-2017-562.pdf
Annals of Oncology10.1093/annonc/mdy06320182951195-1202Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxaneM. Martin, M. Campone, I. Bondarenko, D. Sakaeva, S. Krishnamurthy, L. Roman, L. Lebedeva, J.-C. Vedovato, M. Aaprohttps://api.elsevier.com/content/article/PII:S0923753419345363?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419345363?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/5/1195/24831754/mdy063.pdf
Breast Cancer Research and Treatment10.1007/s10549-010-1152-020101241177-186Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapyMark Clemons, Anil A. Joy, Radhi Abdulnabi, Mauricio Kotliar, Jodi Lynch, Johan P. Jordaan, Neill Iscoe, Karen Gelmonhttp://link.springer.com/content/pdf/10.1007/s10549-010-1152-0.pdf, http://link.springer.com/article/10.1007/s10549-010-1152-0/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10549-010-1152-0
Annals of Oncology10.1093/annonc/mdr40520122351164-1169A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancerA.G. Pallis, I. Boukovinas, A. Ardavanis, I. Varthalitis, N. Malamos, V. Georgoulias, D. Mavroudishttps://api.elsevier.com/content/article/PII:S0923753419346873?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419346873?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/23/5/1164/13785614/mdr405.pdf
The Lancet Oncology10.1016/s1470-2045(13)70154-2201314111077-1085Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialDavid Cunningham, Istvan Lang, Eugenio Marcuello, Vito Lorusso, Janja Ocvirk, Dong Bok Shin, Derek Jonker, Stuart Osborne, Niko Andre, Daniel Waterkamp, Mark P Saundershttps://api.elsevier.com/content/article/PII:S1470204513701542?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204513701542?httpAccept=text/plain
The Breast10.1016/j.breast.2018.04.01020184067-75A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOPToshimi Takano, Junji Tsurutani, Masato Takahashi, Takeharu Yamanaka, Kazuko Sakai, Yoshinori Ito, Junya Fukuoka, Hideharu Kimura, Hidetaka Kawabata, Kenji Tamura, Koji Matsumoto, Kenjiro Aogi, Kazuhiko Sato, Kazuto Nishio, Kazuhiko Nakagawa, Toshiaki Saekihttps://api.elsevier.com/content/article/PII:S0960977618300730?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977618300730?httpAccept=text/plain
The Breast Journal10.1111/tbj.120982013193240-249A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with AnthracyclinesMario Campone, Natalya Dobrovolskaya, Serjei Tjulandin, Shin-Chen Chen, Sameul Fourie, Fawzia Mefti, Maria Konstantinova, Florence Lefresne, Nadege Meheust, Jacek Jassemhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ftbj.12098, http://onlinelibrary.wiley.com/wol1/doi/10.1111/tbj.12098/fullpdf
Clinical Breast Cancer10.3816/cbc.2007.n.003200776465-470Phase II Trial of Capecitabine and Weekly Paclitaxel in Patients with Metastatic Breast Cancer Previously Treated with Every-3-Week Taxane TherapyJoanne L. Blum, E. Claire Dees, Svetislava J. Vukelja, Mammo Amare, David P. Gill, Richard T. McMahon, Des Ilegbodu, Lina Asmar, Joyce A. O'Shaughnessyhttps://api.elsevier.com/content/article/PII:S1526820911707327?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911707327?httpAccept=text/plain
Cancer Chemotherapy and Pharmacology10.1007/s00280-010-1362-52010663597-603Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatmentJiayu Wang, Ying Fan, Binghe Xuhttp://link.springer.com/content/pdf/10.1007/s00280-010-1362-5.pdf, http://link.springer.com/article/10.1007/s00280-010-1362-5/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-010-1362-5
Annals of Oncology10.1016/s0923-7534(20)34361-1201223ixe5Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)X. Pivot, V. Semiglazov, B. ┼╗urawski, R. Allerton, A. Fabi, E. Ciruelos, R. Parikh, M. DeSilvio, S. Santillana, R. Swabyhttps://api.elsevier.com/content/article/PII:S0923753420343611?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420343611?httpAccept=text/plain